Fasenra vs Xolair
Side-by-side cost comparison based on Medicare Part D data
Fasenra
Benralizumab
Manufactured by AstraZeneca
Xolair
Omalizumab
Manufactured by Genentech/Novartis
Xolair costs 42% less per claim than Fasenra ($1,657.00 vs $2,836.00). A generic version of Xolair is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Fasenra | Xolair |
|---|---|---|
| Avg Cost Per Claim | $2,836.00 | $1,657.00 |
| Total Medicare Spending | $987.0M | $1.0B |
| Total Beneficiaries | 32,000 | 62,000 |
| Total Claims | 348,000 | 624,000 |
| Annual Cost/Patient | $30,844.00 | $16,677.00 |
| Year-over-Year Change | +18.6% | +5.4% |
| Generic Available | No | Yes |
| Patent Expiration | Nov 14, 2031 | Jun 20, 2017 |
| Manufacturer | AstraZeneca | Genentech/Novartis |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Benralizumab | Omalizumab |
Fasenra vs Xolair: What the Data Shows
Fasenra (Benralizumab) and Xolair (Omalizumab) are both used to treat asthma/copd. Based on Medicare Part D data, Xolair costs $1,657.00 per claim, which is 42% less than Fasenra at $2,836.00 per claim.
Medicare spent $987.0M on Fasenra and $1.0B on Xolair. In terms of patient reach, Xolair serves more beneficiaries (62,000 vs 32,000).
Year-over-year spending changed +18.6% for Fasenra and +5.4% for Xolair. Fasenra saw significant spending growth, suggesting increased utilization or price increases.
Xolair has a generic available, while Fasenra remains brand-only until its patent expires Nov 14, 2031.
Frequently Asked Questions
Xolair is cheaper at $1,657.00 per claim, compared to $2,836.00 for Fasenra. That makes Xolair about 42% less expensive per claim based on Medicare Part D data.
Yes, both Fasenra and Xolair are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Xolair has a generic version (Omalizumab) available, which is typically much cheaper. Fasenra is currently brand-only, with patent expiring Nov 14, 2031.
Medicare Part D spent $987.0M on Fasenra covering 32,000 beneficiaries, and $1.0B on Xolair covering 62,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.